Dendritic Cell-Based Therapy Using LY6E Peptide with a Putative Role Against Colorectal Cancer.
LY6E
colorectal cancer
dendritic cell
dendritic cell tumor-associated antigen therapy
Journal
ImmunoTargets and therapy
ISSN: 2253-1556
Titre abrégé: Immunotargets Ther
Pays: New Zealand
ID NLM: 101606565
Informations de publication
Date de publication:
2020
2020
Historique:
received:
15
01
2020
accepted:
08
05
2020
entrez:
18
6
2020
pubmed:
18
6
2020
medline:
18
6
2020
Statut:
epublish
Résumé
Albeit early stage gastrointestinal (GI) carcinomas have a good prognosis if treated with surgery, diagnosis is often confirmed at a late stage and efficacious drugs are lacking. Recent progress in immune-based therapies has focused on dendritic cells (DCs), aiming to elicit tumor-specific responses by inducing immunological memory. Our previous microarray study indicated that a biomarker, termed lymphocyte antigen-6E (LY6E), is commonly overexpressed in two potentially lethal GI cancers: those of colon and stomach. In this study, we examined the antigenic potency of LY6E in stimulating DCs. Following isolation, differentiation, and maturation of mononuclear cells, DCs were pulsed with LY6E peptide, a protein related to major histocompatibility complex (MHC) class I/II. Subsequently, DCs were co-cultured with mouse splenocytes to assess antigen-specific T-cell proliferation. Elucidated cytotoxic T-lymphocyte responses were assessed using subcutaneous colorectal murine tumor models. Our in vitro results suggest that DCs loaded with LY6E peptide antigen are capable of stimulating and inducing proliferation of murine T-cells. Furthermore, our in vivo results demonstrate that LY6E peptide has a substantial impact on provoking immune responses against induced colon cancer in mice. In conclusion, based on the overexpression of LY6E in colorectal, gastric, and pancreatic cancers, the role of this peptide should be further investigated with a goal of developing new therapies for these challenging diseases.
Identifiants
pubmed: 32548075
doi: 10.2147/ITT.S245913
pii: 245913
pmc: PMC7250699
doi:
Types de publication
Journal Article
Langues
eng
Pagination
95-104Informations de copyright
© 2020 Tokhanbigli et al.
Déclaration de conflit d'intérêts
We declare that we have no conflicts of interest.
Références
Gastroenterol Hepatol Bed Bench. 2015 Winter;8(1):19-27
pubmed: 25584172
Clin Exp Immunol. 2009 Jul;157(1):128-38
pubmed: 19659778
BMB Rep. 2012 Nov;45(11):595-603
pubmed: 23186997
Cancer Immun. 2013 Jul 15;13:15
pubmed: 23882160
Oncotarget. 2015 Sep 15;6(27):23462-79
pubmed: 26405163
J Leukoc Biol. 2013 Oct;94(4):585-94
pubmed: 23543767
Surg Oncol. 2012 Sep;21(3):164-71
pubmed: 22521560
Nucleic Acids Res. 2015 Jan;43(Database issue):D405-12
pubmed: 25300482
Anticancer Res. 2010 Dec;30(12):5091-7
pubmed: 21187495
Dev Immunol. 1998;6(1-2):149-56
pubmed: 9716916
Pancreatology. 2005;5(4-5):370-9
pubmed: 15983444
Clin Cancer Res. 2004 Apr 15;10(8):2645-51
pubmed: 15102666
J Surg Oncol. 2017 Apr;115(5):619-630
pubmed: 28194798
Oncotarget. 2016 Oct 4;7(40):65837-65848
pubmed: 27589564
Sci Rep. 2017 Jun 9;7(1):3165
pubmed: 28600530
Mol Biosyst. 2017 Oct 24;13(11):2277-2288
pubmed: 28868547
Clin Cancer Res. 2015 Jul 15;21(14):3252-62
pubmed: 25862760
Clin Cancer Res. 2002 Nov;8(11):3394-400
pubmed: 12429626
J Immunol Methods. 1999 Feb 1;223(1):77-92
pubmed: 10037236
Cancer Res. 2016 Jun 1;76(11):3376-86
pubmed: 27197181
Stem Cell Res Ther. 2015 Aug 08;6:140
pubmed: 26253429
Oncotarget. 2016 Mar 8;7(10):11165-93
pubmed: 26862846
Clin Cancer Res. 2001 Aug;7(8):2277-84
pubmed: 11489802
Cell Physiol Biochem. 2018;45(3):1219-1229
pubmed: 29448250
J Natl Cancer Inst. 1992 Jul 15;84(14):1084-91
pubmed: 1619682
Eur Rev Med Pharmacol Sci. 2010 Apr;14(4):249-58
pubmed: 20496531
Nat Immunol. 2000 Oct;1(4):311-6
pubmed: 11017102
Updates Surg. 2016 Mar;68(1):7-11
pubmed: 27067591
World J Gastroenterol. 2016 Nov 28;22(44):9694-9705
pubmed: 27956793
Oncotarget. 2017 Dec 14;8(70):115215-115229
pubmed: 29383154